Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | An insight into MyeloMATCH: enabling rapid advancements in the treatment of myeloid malignancies

Harry Erba, MD, PhD, Duke University, Durham, NC, shares some insights into MyeloMATCH: the National Cancer Institute (NCI) Myeloid Malignancies Molecular Analysis for Therapy Choice precision medicine clinical trial, which aims to rapidly advance therapeutic options for patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Using advanced DNA sequencing technologies, Dr Erba explains that MyeloMATCH will allow patients to enrol in specific targeted treatment trials and overcome the challenge of long waiting periods, providing patients with treatment options at an early stage in disease. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

ImmunoGen: Consultancy, Research Funding; Incyte: Consultancy, Speakers Bureau; Jazz Pharmaceuticals: Consultancy, Research Funding, Speakers Bureau; MacroGenics: Consultancy, Research Funding; Novartis: Consultancy, Research Funding, Speakers Bureau; Covance (Abbvie): Consultancy, Other: Independent Review Committee, Research Funding; Janssen Oncology: Consultancy; Trillium Therapeutics: Consultancy; Takeda: Consultancy; Kura Oncology: Consultancy, Research Funding; Forma Therapeutics: Research Funding; Gilead/Forty Seven: Research Funding; PTC therapeutics: Research Funding; ALX Oncology: Research Funding; Pfizer: Consultancy; Glycomimetics: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Daiichi Sankyo: Consultancy, Research Funding; Celgene: Consultancy, Other, Speakers Bureau; Astellas Pharma: Consultancy; Amgen: Consultancy, Research Funding; Agios: Consultancy, Research Funding, Speakers Bureau; Abbvie: Consultancy, Research Funding, Speakers Bureau; Celgene: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau.